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Abstract
Background: Molecular and epidemiological evidence demonstrate that altered gene expression and single
nucleotide polymorphisms in the apoptotic pathway are linked to many cancers. Yet, few studies emphasize the
interaction of variant apoptotic genes and their joint modifying effects on prostate cancer (PCA) outcomes. An
exhaustive assessment of all the possible two-, three- and four-way gene-gene interactions is computationally
burdensome. This statistical conundrum stems from the prohibitive amount of data needed to account for multiple
hypothesis testing.
Methods: To address this issue, we systematically prioritized and evaluated individual effects and complex
interactions among 172 apoptotic SNPs in relation to PCA risk and aggressive disease (i.e., Gleason score ≥ 7 and
tumor stages III/IV). Single and joint modifying effects on PCA outcomes among European-American men were
analyzed using statistical epistasis networks coupled with multi-factor dimensionality reduction (SEN-guided MDR).
The case-control study design included 1,175 incident PCA cases and 1,111 controls from the prostate, lung, colo-
rectal, and ovarian (PLCO) cancer screening trial. Moreover, a subset analysis of PCA cases consisted of 688
aggressive and 488 non-aggressive PCA cases. SNP profiles were obtained using the NCI Cancer Genetic Markers of
Susceptibility (CGEMS) data portal. Main effects were assessed using logistic regression (LR) models. Prior to
modeling interactions, SEN was used to pre-process our genetic data. SEN used network science to reduce our
analysis from > 36 million to < 13,000 SNP interactions. Interactions were visualized, evaluated, and validated using
entropy-based MDR. All parametric and non-parametric models were adjusted for age, family history of PCA, and
multiple hypothesis testing.
Results: Following LR modeling, eleven and thirteen sequence variants were associated with PCA risk and
aggressive disease, respectively. However, none of these markers remained significant after we adjusted for
multiple comparisons. Nevertheless, we detected a modest synergistic interaction between AKT3 rs2125230-PRKCQ
rs571715 and disease aggressiveness using SEN-guided MDR (p = 0.011).
Conclusions: In summary, entropy-based SEN-guided MDR facilitated the logical prioritization and evaluation of
apoptotic SNPs in relation to aggressive PCA. The suggestive interaction between AKT3-PRKCQ and aggressive PCA
requires further validation using independent observational studies.
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Prostate cancer (PCA) is the most frequently diagnosed
cancer and the 2
nd leading cause of cancer-related deaths
among men in the United States [1]. The American Can-
cer Society estimates that 26-29% of all new cancer cases
and cancer-related deaths are attributed to PCA cancer.
Well established PCA risk factors include older age,
black race, and family history of PCA. However, other
potential contributors of this disease may include lifestyle
and genetic factors as well as imbalances within impor-
tant biological pathways.
Apoptosis or programmed cell death is one such biologi-
cal process that moderates cell differentiation, proliferation,
death, whole body homeostasis and tumorigenesis [2-4].
This process is controlled by cell death (e.g. BAD, CASP,
BIK) and cell survival proteins (e.g. BCL2, NFB, AKT3)
that induce or block apoptosis, respectively, as summarized
in Table 1 [2,3,5]. Decreased apoptotic cell death and
increased cell proliferation may lead to clonal expansion
and tumor growth [2]. Failure to undergo apoptosis permits
survival of transformed cells, leading to subsequent genetic
alteration, genomic instability, and ultimately a more inva-
sive cancer phenotype [3]. Imbalances in apoptosis-related
genes may play an important role in PCA susceptibility as
well as disease progression. For example, several indepen-
dent studies have shown that overexpression of cell survival
indicators (e.g., BCL-2, CARD8, IKBKE, PRKCQ, and
PIK3CB, AKT3) or down-regulation of cell death markers
(e.g., BCL2L14) are associated with more aggressive pheno-
types, higher Gleason grade, increased tumor progression,
and poor PCA prognosis [6-19].
There is mounting epidemiological evidence that genetic
alterations in apoptosis-related genes play an important
role in tumorigenesis. Apoptosis-associated sequence
variants, when considered individually, may minimally
influence the risk of developing numerous cancers, such
as multiple myeloma, squamous cell carcinoma, chronic
lymphocytic leukemia, non-Hodgkin lymphoma, colorec-
tal, ovarian, breast, pancreatic, and non-small cell lung
[20-37]. However, the impact of individual apoptosis-
related single nucleotide polymorphisms (SNPs) and their
interactions on PCA outcomes remains understudied.
Genome wide association studies (GWAS), involving the
evaluation of millions of SNPs within various biological
pathways, has resulted in the detection of numerous PCA
susceptibility loci [38]. However, most GWAS and PCA
epidemiology studies place emphasis on individual SNP
effects. Consequently, researchers often ignore the fact
that complex diseases such as PCA are governed by com-
plex gene-gene and gene-environment interactions within
distinct biological pathways. Consequently, we sought to
evaluate millions of interactions among apoptosis SNPs
and their joint modifying impact on PCA risk and disease
progression.
This report focuses on the impact of complex interac-
tions among 172 apoptosis-related SNPs on PCA among
2,286 European-American male participants of the Cancer
Genetic Markers of Susceptibility Study (CGEMS). The
exhaustive assessment of all possible two-, three-, and
four-way interactions among 172 SNPs, totaling more
than 36 million SNP combinations is computationally
burdensome. The statistical challenge stems from the pro-
hibitive amount of data needed for multiple hypothesis
testing. To address this issue, for the first time, we use sta-
tistical epistasis networks (SEN) guided multi-factor
dimensionality reduction (MDR) to efficiently pre-process
our genetic data, prior to modeling higher order interac-
tions. As previously reported by Hu and co-workers
(2011), SEN uses network science to generate a large con-
nected cluster of pairwise interactions embedded within a
genetic dataset [39]. The resulting network, consisting of a
subset of high susceptibility SNPs, is used to guide SNP
interactions using MDR. MDR is a rigorous statistical tool
designed, in part, to evaluate main effects and complex
interactions in relation to discrete outcomes [40-48]. This
report may serve as a foundation for researchers interested
in a state-of the art bioinformatics technique, namely
SEN-guided MDR, which facilitates the logical prioritiza-
tion of SNPs for gene-gene interaction analyses in relation
to PCA susceptibility and prognosis.
Results
Cancer Genetic Markers of Susceptibility (CGEMS)
Population Description
CGEMS study participants consisted of middle aged non-
Hispanic Caucasian men, ranging in age from 55 to 81.
Relative to control subjects, men diagnosed with PCA were
more likely to have a family history of the disease (11.4%
versus 6.3%), PSA levels ≥ 4 ng/ml (48.5% versus 6.5%),
and abnormal DRE exams (60.7% versus 46.2%) [data not
shown]. Men with aggressive PCA had both a Gleason
score ≥ 7 and tumor stage III/IV. Although non-aggressive
PCA cases primarily had a Gleason score < 7 and tumor
stage I/II, a small percentage (1.8%) of them had a Gleason
score > 6 and a tumor stage I/II. Among cases, there were
no significant differences in family history of disease or
PSA levels between men diagnosed comparing men with
aggressive and non-aggressive disease (data not shown).
The vast majority of subjects with aggressive PCA had
higher Gleason scores than subjects with non-aggressive
PCA, although 9 of the 488 non-aggressive cases (1.08%)
had a Gleason score greater than 6.
Single SNP Effects
We examined 172 apoptosis-related sequence variants in
relation to PCA risk and disease aggressiveness, as
shown in Tables 2 and 3. Age and family history of
PCA did not modify the relationship between the
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Page 2 of 15Table 1 Selected genes involved in the regulation of apoptosis
Gene Function*
Pro- & Anti-
apoptotic
Tumor Protein 53 (TP53) Transcriptionally regulates target genes that induce cell cycle
arrest, apoptosis, senescence, DNA repair, or changes in
metabolism in response to cellular stresses.
Tumor Necrosis Factor
(TNF)
Binds and functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR to regulate cell
proliferation, differentiation,
and apoptosis.
PRKCQ Protein kinase C family member; substrate for Caspase-3; phosphorylates BAD and required to activate
NFB (via CARD11 phosphorylation) and AP-1.
Pro-apoptotic FAS &FAS Ligand (FASL) Death domain-containing receptor, binding of FASL to FAS
allows the formation of a death-inducing signaling complex.
CASPASE (CASP) Gene family involved in the execution of apoptosis. There are 2
classes of caspases, which include: initiators (e.g., CASP2, CASP8, CASP9, and CASP10) and effectors (e.g.,
CASP3, CASP6, CASP7). Initiator caspases activate pro-forms of effector caspases,
enabling effectors to trigger the apoptosis process.
CARD8 (Caspase
recruitment domain
family, member 8)
CARD family protein; involved in various pathways which
regulate caspases or NFB; isoforms interact with caspases to
signal apoptosis.
BCL2-associated X (BAX) Forms a heterodimer with BCL2 and functions as an apoptotic
activator involved mitochondrial release of cytochrome c.
BCL2-antagonist/killer 1
(BAK1)
Induces apoptosis by increasing cytochrome c release; interacts
with the TP53 after exposure to cell stress.
BCL2-associated agonist of
cell death (BAD)
Forms heterodimers with BCLXL and BCL2 to reverse their death repressor activity.
BCL2-like 10 (BCL2L10) Interacts with BCL2 proteins (e.g., BCL2, BCL2L1/BCLXL, and
BAX).
BCL2-like 11 (BCL2L11) (aka BIM); Interacts with other members of the BCL2 protein
family (e.g., BCL2, BCL2L1/BCLXL, and MCL1) to act as an
apoptosis activator.
BCL2-like 14 (BCL2L14) Apoptosis facilitator; interacts with BCL2 family members; p53-
target gene.
BH3 interacting domain
death agonist (BID)
Induced by CASP8; CASP8 cleaves the protein encoded by this
gene, and the COOH-terminal part translocates to mitochondria,
which triggers cytochrome c release.
BCL2-interacting killer
(BIK)
Interacts with survival-promoting proteins to enhance
programmed cell death.
BCL2/adenovirus E1B
19 kDa interacting protein
3-like (BNIP3L)
(aka NIX); BCL2/adenovirus E1B 19 kd-interacting protein (BNIP)
gene that may function simultaneously with BNIP3 and play a
role in tumor suppression.
PRKCD Translocates into nucleus during apoptosis. Nuclear PRKCD
regulates initiation of cytosolic apoptosis machinery, and
subsequent caspase activation and DNA fragmentation.
Anti-apoptotic AKT3 Phosphorylate and inactivate BAD. Activates NFB via IB kinase regulation. Regulates cell signals in
response to insulin and
growth factors.
B-cell CL/lymphoma 2 (BCL2) Blocks the release of pro-apoptotic cytochrome c and caspase
activation.
NFB Inhibit caspases 3, 6, 7 stimulation via IAP (inhibitor of
apoptosis) activation.
PIK3CB Interacts with growth factor receptors; activates AKT3; target
for PRKC.
RAF1 Inhibits BIM and BAD activation via ERK1/2 stimulation.
BCL2-related protein A1
(BCL2A1)
Reduces cytochrome c release from mitochondria and blocks
caspase activation.
Baculoviral IAP repeat-
containing 2 (BIRC2)
(aka CIAP1); Inhibits apoptosis by binding to tumor necrosis
factor receptor-associated factors TRAF1 and TRAF2.
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PRKCE Blocks mitochondrial-dependent caspase activation;
phosphorylates and activates RAF-1; phosphorylates and
inactivates BAD; activates AKT via DNA-dependent protein kinase
(DNA-PK).
IKBKE Induces BCL-2 expression via NFB signaling and interaction.
*Gene functions based on NCBI and/or selected publications (as indicated in the manuscript)
Table 2 Association of apoptosis SNPs with prostate cancer
Marker (Alleles
and position)
Allele Cases N (%) Controls N (%) OR (95%CI) Adj OR (95%CI)* p value Bonf.
p value
p trend Permut.
p value
BIK AA 944 (81.2) 855 (77.0) 1.00 (reference) 1.00 (reference) 0.048 1.000 0.017 1.000
rs4988366 AG 208 (17.9) 244 (22.0) 0.77 (0.63-0.95) 0.78 (0.63-0.96) 0.014
A41830193G GG 12 (1.0) 14 (1.3) 0.78 (0.36-1.69) 0.79 (0.36-1.71) 0.523
AG + GG 220 (18.9) 258 (23.2) 0.78 (0.63-0.95) 0.78 (0.64-0.96) 0.014 1.000 0.831
BNIP3L CC 556 (47.8) 477 (42.9) 1.00 (reference) 1.00 (reference) 0.041 1.000 0.012 0.998
rs10503786 TC 480 (41.3) 489 (44.0) 0.84 (0.71-1.00) 0.85 (0.71-1.01) 0.055
C26325853T TT 103 (8.9) 122 (11.0) 0.72 (0.54-0.97) 0.73 (0.55-0.98) 0.029
TC + TT 583 (50.1) 611 (55.0) 0.82 (0.70-0.97) 0.82 (0.70-0.97) 0.020 1.000 0.928
CASP9 CC 320 (27.5) 348 (31.3) 1.00 (reference) 1.00 (reference) 0.075 1.000 0.023 1.000
rs1052571 TC 589 (50.6) 553 (49.8) 0.88 (0.71-1.10) 0.88 (0.71-1.09) 0.265
C15595919T TT 253 (21.8) 210 (18.9) 0.76 (0.60-0.97) 0.75 (0.59-0.95) 0.026
TC + CC 842 (72.4) 763 (68.7) 0.84 (0.68-1.03) 0.83 (0.68-1.02) 0.090 1.000 0.998
IKBKE CC 837 (72.0) 740 (66.6) 1.00 (reference) 1.00 (reference) 0.017 1.000 0.005 0.903
rs1539243 TC 291 (25.0) 325 (29.3) 0.79 (0.66-0.95) 0.78 (0.65-0.95) 0.014
C203036182T TT 36 (3.1) 47 (4.2) 0.68 (0.43-1.06) 0.68 (0.43-1.06) 0.086
TC + TT 327 (28.1) 372 (33.5) 0.78 (0.65-0.93) 0.77 (0.64-0.92) 0.006 0.943 0.522
PRKCE TT 841 (72.3) 788 (70.9) 1.00 (reference) 1.00 (reference) 0.030 1.000 0.139 0.987
rs608139 TC 304 (26.1) 288 (25.9) 0.99 (0.82-1.19) 0.98 (0.51-1.19) 0.909
T45789207C CC 18 (1.5) 36 (3.2) 0.47 (0.26-0.83) 0.50 (0.28-0.88) 0.010
TC + CC 322 (27.7) 324 (29.2) 0.93 (0.78-1.12) 0.93 (0.78-1.12) 0.435 1.000 1.000
PRKCE AA 556 (47.8) 482 (43.4) 1.00 (reference) 1.00 (reference) 0.045 1.000 0.013 1.000
rs935673 AG 503 (43.3) 503 (45.3) 0.87 (0.73-1.03) 0.87 (0.73-1.04) 0.107
A46034008G GG 105 (9.0) 128 (11.5) 0.71 (0.53-0.95) 0.71 (0.53-0.95) 0.019
AG + GG 608 (52.3) 631 (56.8) 0.84 (0.71-0.99) 0.84 (0.71-0.99) 0.034 1.000 0.991
TNFRSF10B GG 547 (47.0) 537 (48.3) 1.00 (reference) 1.00 (reference) 0.055 1.000 0.253 1.000
rs1001793 AG 448 (38.5) 458 (41.2) 0.96 (0.80-1.15) 0.96 (0.80-1.14) 0.653
G22956894A AA 131 (11.3) 93 (8.4) 1.38 (1.03-1.85) 1.38 (1.03-1.85) 0.029
AG + AA 579 (49.8) 551 (49.6) 1.01 (0.86-1.19) 1.03 (0.87-1.22) 0.892 1.000 1.000
TNFRSF1A AA 375 (32.2) 376 (33.8) 1.00 (reference) 1.00 (reference) 0.079 1.000 0.070 1.000
rs4149576 AG 545 (46.9) 545 (79.1) 0.78 (0.62-0.98) 0.79 (0.63-0.99) 0.034
A6319376G GG 234 (20.1) 183 (16.5) 0.78 (0.61-0.99) 0.79 (0.62-1.01) 0.043
AG + GG 779 (67.0) 728 (65.5) 0.78 (0.63-0.97) 0.79 (0.63-0.98) 0.024 1.000 0.854
TNFRSF1A TT 326 (28.0) 270 (24.3) 1.00 (reference) 1.00 (reference) 0.087 1.000 0.205 1.000
rs4149577 TC 571 (49.1) 591 (5302) 0.80 (0.66-0.98) 0.80 (0.66-0.98) 0.027
T6317783C CC 265 (22.8) 251 (22.6) 0.87 (0.69-1.11) 0.88 (0.70-1.12) 0.266
TC + CC 836 (71.9) 842 (75.8) 0.82 (0.68-0.99) 0.83 (0.68-1.00) 0.038 1.000 0.141
TNFSF10 GG 630 (54.2) 668 (60.1) 1.00 (reference) 1.00 (reference) 0.026 1.000 0.014 0.977
rs4894559 AG 456 (39.2) 380 (34.2) 1.27 (1.07-1.51) 1.27 (1.06-1.51) 0.007
G173716071A AA 76 (6.5) 65 (5.9) 1.24 (0.88-1.78) 1.23 (0.87-1.74) 0.227
AG + AA 532 (45.7) 445 (40.1) 1.26 (1.06-1.49) 1.26 (1.07-1.49) 0.007 1.000 0.594
Abbreviations: Bonf., Bonferroni; Permut., Permutation; *adjusted for age and family history of PCA
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Marker (Alleles
and position)
Allele Cases N (%) Controls N (%) OR (95%CI) Adj OR (95%CI)* p value Bonf.
p value
p trend Permut.
p value
AKT3 CC 295 (42.9) 244 (50.0) 1.00 (reference) 1.00 (reference) 0.065 1.000 0.028 1.000
rs10157763 TC 307 (44.7) 192 (39.3) 1.31 (1.02-1.67) 1.33 (1.04-1.71) 0.027
C240321082T TT 75 (10.9) 45 (9.2) 1.21 (0.82-1.78) 1.39 (0.92-2.09) 0.344
TC + TT 382 (55.6) 237 (48.6) 1.32 (1.04-1.66) 1.34 (1.06-1.70) 0.020 1.000 0.943
AKT3 GG 438 (63.8) 345 (70.7) 1.00 (reference) 1.00 (reference) 0.005 0.853 0.038 0.493
rs10927067 AG 227 (33.0) 119 (24.4) 1.50 (1.15-1.95) 1.51 (1.16-1.96) 0.002
G240249285A AA 20 (2.9) 19 (3.9) 0.83 (0.44-1.58) 0.82 (0.43-1.57) 0.568
AG + AA 247 (36.0) 138 (28.3) 1.43 (1.12-1.84) 1.41 (1.10-1.82) 0.005 0.977 0.511
AKT3 TT 483 (70.3) 380 (77.9) 1.00 (reference) 1.00 (reference) 0.002 0.356 0.023 0.250
rs12031994 TC 192 (27.9) 94 (19.3) 1.61 (1.21-2.13) 1.61 (1.22-2.14) 0.009
T240243350C CC 13 (1.9) 14 (2.9) 0.73 (0.34-1.57) 0.73 (0.34-1.57) 0.422
TC + CC 205 (29.8) 108 (22.1) 1.51 (1.15-1.98) 1.50 (0.15-1.96) 0.003 0.548 0.372
AKT3 GG 436 (63.5) 341 (69.9) 1.00 (reference) 1.00 (reference) 0.030 1.000 0.068 0.984
rs2125230 AG 231 (33.6) 129 (26.4) 1.40 (1.09-1.81) 1.40 (1.08-1.82) 0.010
G240211889A AA 21 (3.1) 18 (3.7) 0.91 (0.48-1.74) 0.91 (0.48-1.74) 0.781
AG + AA 252 (36.7) 147 (30.1) 1.35 (1.06-1.73) 1.34 (1.05-1.72) 0.017 1.000 0.938
AKT3 GG 296 (43.1) 238 (48.8) 1.00 (reference) 1.00 (reference) 0.083 1.000 0.027 1.000
rs2125231 AG 314 (45.7) 203 (41.6) 1.24 (0.97-1.59) 1.25 (0.98-1.60) 0.082
G240088340A AA 75 (10.9) 42 (8.6) 1.43 (0.95-2.17) 1.44 (0.95-2.18) 0.087
AG + AA 389 (56.6) 245 (50.2) 1.29 (1.02-1.63) 1.28 (1.01-1.62) 0.031 1.000 0.992
AKT3 CC 295 (42.9) 243 (49.8) 1.00 (reference) 1.00 (reference) 0.060 1.000 0.022 1.000
rs2345994 TC 312 (45.4) 195 (40.0) 1.32 (1.03-1.69) 1.32 (1.03-1.70) 0.028
C240258316T TT 78 (11.4) 45 (9.2) 1.43 (0.95-2.14) 1.44 (0.95-2.16) 0.084
TC + TT 390 (56.8) 240 (49.2) 1.32 (1.05-1.67) 1.35 (1.06-1.70) 0.018 1.000 0.946
AKT3 CC 435 (63.3) 348 (71.3) 1.00 (reference) 1.00 (reference) 0.009 1.000 0.029 0.714
rs4132509 AC 227 (33.0) 121 (24.8) 1.50 (1.15-1.95) 1.51 (1.16-1.96) 0.002
C240269125A AA 18 (2.6) 16 (3.3) 0.90 (0.45-1.79) 0.88 (0.44-1.75) 0.764
AC + AA 245 (35.7) 137 (28.1) 1.43 (1.11-1.84) 1.44 (1.11-1.85) 0.005 1.000 0.581
BCL2L14 GG 436 (63.5) 343 (70.3) 1.00 (reference) 1.00 (reference) 0.041 1.000 0.025 0.998
rs885720 AG 231 (33.6) 131 (26.8) 1.39 (1.07-1.79) 1.39 (1.08-1.80) 0.012
G12139366A AA 21 (3.1) 14 (2.9) 1.18 (0.59-2.25) 1.20 (0.60-2.39) 0.639
AG + AA 252 (36.7) 145 (29.7) 1.37 (1.07-1.76) 1.37 (1.07-1.76) 0.013 1.000 0.843
CARD8 CC 462 (67.2) 362 (74.2) 1.00 (reference) 1.00 (reference) 0.016 1.000 0.005 0.882
rs10405717 TC 202 (29.4) 111 (22.7) 1.45 (1.11-1.90) 1.45 (1.11-1.90) 0.007
C53443620T TT 21 (3.1) 10 (2.0) 1.70 (0.79-3.68) 1.70 (0.79-3.68) 0.173
TC + TT 223 (32.5) 121 (24.8) 1.45 (1.12-1.89) 1.47 (1.13-1.91) 0.005 0.754 0.459
IKBKE TT 251 (36.5) 209 (42.8) 1.00 (reference) 1.00 (reference) 0.008 1.000 0.003 0.682
rs11578093 TG 332 (48.3) 233 (47.7) 1.19 (0.93-1.52) 1.17 (0.91-1.50) 0.177
T203059049G GG 102 (6.0) 46 (9.4) 1.85 (1.25-2.74) 1.81 (1.22-2.69) 0.002
TG + GG 434 (63.2) 279 (57.2) 1.31 (1.03-1.66) 1.27 (1.00-1.62) 0.027 1.000 0.982
IKBKE CC 502 (73.1) 341 (69.9) 1.00 (reference) 1.00 (reference) 0.048 1.000 0.076 1.000
rs1539243 TC 172 (25.0) 125 (25.6) 0.93 (0.71-1.22) 0.95 (0.73-1.24) 0.622
C203036182T TT 14 (2.0) 22 (4.5) 0.43 (0.22-0.86) 0.44 (0.22-0.88) 0.016
TC + TT 186 (27.1) 147 (30.1) 0.86 (0.66-1.11) 0.88 (0.68-1.13) 0.244 1.000 1.000
PIK3CB TT 215 (31.3) 131 (26.8) 1.00 (reference) 1.00 (reference) 0.060 1.000 0.021 1.000
rs500687 TC 334 (48.6) 234 (48.0) 0.87 (0.66-1.14) 0.87 (0.66-1.14) 0.318
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aggressive disease. Inheritance of one or more
TNFRSF10B rs1001793 or TNFSF10 rs4894559 A alleles
was nominally associated with a 1.23-1.38 fold increase
in PCA risk (p ≤ 0.039), as shown in Table 2. Whereas,
eight apoptosis-related SNPs were associated with a mod-
erate 18-50% reduction in disease susceptibility [BIK
rs4988366 AG & AG + GG; BNIP3L rs10503786 TT &
TC + TT; CASP9 rs1052571 TT; IKBKE rs1539243 TC
& TC + TT; PRKCE rs608139 CC; PRKCE rs935673 GG &
AG + GG; TNFRSF1A rs4149576 AG, GG, & AG + GG;
and TNFRSF1A rs4149577 TC & TC + CC]( p≤ 0.043).
However, after applying Bonferonni correction, none of
these findings remained statistically significant under the
per-allele, dominant and recessive genetic models.
In terms of disease progression, eleven apoptosis SNPs
were modestly associated with a 1.28-1.81 fold increase
in the risk of developing aggressive PCA [AKT3
rs10157763 TC & TC + TT; AKT3 rs10927067 AG &
AG + AA; AKT3 rs12031994 TC & TC + CC;AKT3
rs2125230 AG & AG + AA; AKT3 rs2125231 AG + AA;
AKT3 rs2345994 TC & TC + CC; AKT3 rs4132509 AC
& AC + AA; BCL2L14 rs885720 AG & AG + AA;
CARD8 rs10405717 TC & TC + TT; IKBKE rs11578093
GG & TG + GG; and RAF1 rs13060691 TG]( p≤ 0.031),
as summarized in Table 3. In addition, possession of
IKBKE rs1539243 TT and PIK3CB rs500687 CC geno-
types were moderately linked with a 44-56% reduction
in aggressive PCA susceptibility (p ≤ 0.019). However,
none of these loci remained significant after adjusting
for multiple comparison bias.
Combined Gene Effects
We investigated the ability of gene-gene interactions to
predict PCA outcomes using statistical epistasis networks
(SEN) guided multifactor dimensionality reduction
(MDR), information gain (IG) measure, and hierarchical
interactions graphs (hIG). SEN was used to generate a net-
work to visualize the genetic architecture of PCA out-
comes, prior to an exhaustive search of SNP interactions.
This approach uses information theory to build an epista-
sis network from the strongest pairwise SNP interactions.
A network, consisting of vertices (i.e., SNPs) joined by
edges (i.e., SNP pairs), enabled us to limit our MDR analy-
sis to a subset of the most informative SNPs in relation to
PCA outcomes. We were unable to build a statistically sig-
nificant epistasis network for PCA susceptibility. However,
the network for aggressive PCA was topographically signif-
icant (p < 0.05), given the results from 1000 permutated
data sets. This network consisted of 91 vertices (i.e., indivi-
dual SNP effects), 80 edges (i.e., pairwise interactions), and
18 total components (i.e., “sub-networks” of vertices and
edges). The largest connected component of the aggressive
PCA SEN diagram involved 24 vertices and 34 edges, as
shown in Figure 1 andAdditional file 1. Consequently,
MDR analysis was limited to < 13,000 interactions among
24 SNPs, instead of more than 36 million interactions for
172 SNPs. SEN-guided MDR revealed complex interac-
tions between AKT3 rs12031994-PRKCQ rs571715 as well
as AKT3 rs12031994-BID rs366542-PRKCQ rs571715 that
were significantly associated with disease aggressiveness (p
≤ 0.009). However, the network and entropy graphs indi-
cated these findings were mainly driven by AKT3
rs12031994.T h i si se v i d e n tb yt h em a r k e r ’s large vertex
size (i.e., large main effect) in the SEN graph (Figure 1)
and a lack of a strong pairwise interaction between AKT3
rs12031994-PRKCQ rs571715 in the entropy graph. The
AKT3-PRKCQ interaction resulted in joint mutual infor-
mation (I) of only 0.54% relative to the mutual information
(I) of 0.87% for AKT3 alone. Therefore, prior to repeating
MDR, we removed the AKT3rs12031994 marker. This
resulted in the detection of a modest synergistic interac-
tion between AKT3 rs2125230-PRKCQ rs571715 (p =
0.011), as shown in Table 4. Based on MDR, this model
was the best two-factor model. It was selected 9 out of 10
times by MDR based on a cross-validation consistency
(CVC) score of 90% and predictive accuracy of 56.3%.
Furthermore, we observed a higher mutual information
for the combined effect of AKT3 rs2125230-PRKCQ
rs571715 (I = 0.66%), in contrast to AKT3 rs2125230 alone
(I = 0.45%) or PRKCQrs571715 alone (I = 0.21%), as
revealed in Figure 2.
To confirm the validity of the SEN results, MDR analy-
sis was also conducted on all 172 SNPs (Figure 1
andAdditional file 1) as well as 148 loci that were not
included in the main component of the network.
Table 3 Association of apoptosis SNPs with aggressive prostate cancer (Continued)
T139942901C CC 134 (19.5) 121 (24.8) 0.67 (0.49-0.94) 0.66 (0.48-0.92) 0.019
TC + CC 468 (68.1) 355 (72.7) 0.81 (0.62-1.04) 0.80 (0.62-1.03) 0.099 1.000 1.000
RAF1 TT 508 (73.9) 377 (77.3) 1.00 (reference) 1.00 (reference) 0.010 1.000 0.473 0.764
rs13060691 TG 167 (24.3) 90 (18.4) 1.38 (1.03-1.84) 1.38 (1.03-1.84) 0.030
T12653013G GG 10 (1.5) 16 (3.3) 0.44 (0.20-0.97) 0.45 (0.20-1.01) 0.060
TG + GG 177 (25.8) 106 (21.7) 1.24 (0.94-1.63) 1.24 (0.94-1.63) 0.123 1.000 1.000
Abbreviations: Bonf., Bonferroni correction; Permut., Permutation; *adjusted for age and family history of PCA (PCA)
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three-, or four- way interaction models (p ≥ 0.184).
Discussion
Previous genome-wide association studies (GWAS) have
identified linkages about 40 PCA loci, including between
PCA genetic alterations detected in the 8q24 region, b-
microseminoprotein (MSMB), and allele -8 of the microsa-
tellite DG8S737 [38]. These studies have limited their
scope to individual SNPs across the entire genome. Such
assessments tend to ignore the genetic architecture of
PCA that potentially involves complex interactions along
key regulatory pathways. For the first time, the current
study evaluates complex interactions among 172 apopto-
sis-related SNPs in relation to PCA risk and disease
aggressiveness among 2,286 European-American men
using SEN-guided MDR. Specifically, SEN was used to
build a topographically significant aggressive PCA epistasis
network, prior to evaluating complex interactions. This
inferred epistasis network consisted of 24 SNPs and 34
pairwise interactions, and reduced MDR analysis from >
36 million to < 13,000 SNP interactions. Consequently, we
observed a non-linear and modest interaction between
AKT3 rs2125230-PRKCQ rs571715 in relation to aggres-
sive PCA. This state-of-the-art bioinformatics technique
facilitates the logical prioritization of SNPs for gene-gene
interaction analyses in relation to complex diseases.
Unfortunately, there are no published reports on the
functional consequence of these two intronic SNPs in
AKT3 and PRKCQ in relation to mRNA stability/expres-
sion protein expression/structure/function or PCA out-
comes. However, we speculate that the AKT3 rs2125230
and PRKCQ rs571715 sequence variants, with minor allele
frequencies ranging from 14.4-22.9 among men of
European descent, may alter transcription regulation, lead-
ing to increased mRNA expression. Increased mRNA/pro-
tein expression AKT3 rs2125230 and PRKCQ rs571715
may cause: decreased apoptosis, an escape of transformed
cells from programmed cell death, increased accumulation
of genetic alterations, genomic instability, and ultimately
an invasive PCA phenotype. Thus, in vitro and in vivo
assays using (short hairpin RNAs) shRNAs or small inter-
fering RNAs (siRNAs) are needed to elucidate the impact
of AKT3-PRKCQ genetic alterations on protein expres-
sion, apoptosis capacity, and prostate tumorigenesis.
The impact of a non-linear interaction along the AKT3
rs2125230-PRKCQ rs571715 axis in relation to aggressive
PCA may be attributed to markers involved in the apopto-
sis signaling pathway. Overexpression of PRKCQ and
AKT3 are associated with invasive cancer phenotypes
[6-19]. In fact, AKT3 is responds to insulin and growth
factors, transduces signals including cell death, and is
upregulated in androgen-independent PCA cell lines [49].
PRKCQ is also associated with apoptosis. In particular
PRKCQ, a protein kinase C (PRKC) family member, pro-
motes cell survival by inactivating BAD (BCL2-associated
agonist of cell death), which subsequently results in NFB
activation.
Although AKT3 and PRKCQ are involved in pro-survi-
val pathways, their interaction is not fully understood.
However, their interactions with other related protein
kinases may offer biological clues on the mechanism by
which AKT3 and PRKCQ synergistically influence aggres-
sive PCA. For example, PRKCQ interacts with another
AKT family member, AKT1, to activate NFB [50]. If the
AKT3-PRKCQ axis has a similar function as other protein
kinases, namely AKT1 and PRKCQ, then these pro-survi-
val markers may synergistically activate NFB. As a result,
activated NFB may enable the tumor to escape pro-
grammed cell death and progress toward an aggressive
PCA phenotype.
Numerous observational studies evaluated the impact of
one or more apoptosis-related SNPs in relation to cancer
outcomes [20-37]. Among 15 case-control studies, less
than 10% of the sequence variants evaluated in the current
study were significantly associated with various tumors,
including of the colon, rectal, ovarian, breast, pancreatic,
and non-small cell lung cancers [20-37]. In particular,
modest cancer risk estimates were observed among 8
apoptosis-related SNPs detected in CASP3, CASP8,
CASP9, TP53, NFKB2,a n dNFKBIA. However, some of
these studies were limited by a small sample size, small
number of analyzed SNPs, or failure to consider the
impact of multiple SNPs on disease susceptibility. In the
current study, there were 24 SNPs detected in 10 apopto-
sis-related genes [i.e., A K T 3 ,B I K ,B N I P 3 L ,C A R D 8 ,
CASP9, IKBKE, PRKCE, TNFSF10,a n dTNFRSF10 (B, D)].
These apoptosis-related SNPs, after adjusting for confoun-
ders, were modestly associated with PCA risk and/or
aggressive disease. Yet, these findings lost statistical signifi-
cance after adjusting for multiple hypothesis testing. Main
effects were not observed for AKT3 rs2125230 and
PRKCQ rs571715 in relation to PCA risk or disease pro-
gression in our study set. Wang and co-workers (2009)
evaluated interactions among 5 apoptosis-related SNPs,
including death receptor 4 (DR4), and pack-years of smok-
ing in relation to bladder cancer using entropy-based
MDR [51]. MDR analysis revealed a significant additive
interaction between DR4 -397 G > T and smoking on
bladder cancer. Unfortunately, this study analyzed a rela-
tively small number of sequence variants in the DR4 apop-
tosis-related gene; hence, making it difficult to compare
study findings. In a post-hoc analysis, we did not observe
any interactions among the selected apoptosis-related
markers and sources of reactive oxygen species, antioxi-
dants, and anti-inflammatory agents, including cigarette
smoking, dietary supplements, aspirin, ibuprofen, and
meat-derived carcinogens (data not shown).
Lavender et al. BMC Medical Genomics 2012, 5:11
http://www.biomedcentral.com/1755-8794/5/11
Page 7 of 15We considered the strengths, limitations and future
directions of the current study. Although SEN-guided
MDR only identified a nominally significant network for
disease aggressiveness in the current study, this approach
overcomes the computational challenge of detecting all
possible two-, three- and four-way SNP combinations
involved in PCA progression. SEN, in the current study,
was used to prioritize > 10 million possible interactions
by focusing on a “sub-network” of informative SNPs in
relation to aggressive PCA. Reduction of our genetic data
set to the most informative markers improved the feasi-
bility to detect interactions that may have otherwise
remained undetected. Unfortunately, the genome-wide
association studies (GWAS) database used for the current
study did not include apoptosis-related sequence variants
(e.g., TNF-308 rs1800629,T N F S F 1 0rs1131532, BCL2
-936 rs2279115) previously reported in published cancer
epidemiology studies [52-54]. Future studies in our
laboratory will focus on high-throughput targeted
sequencing to evaluate the impact of novel and com-
monly reported sequence variants on PCA susceptibility
and disease prognosis. In light of recent GWAS reports,
it is tempting to assume that extremely large case-control
study sets, involving tens of thousands subjects are
required to evaluate millions of SNP interactions in rela-
tion to PCA outcomes. However, the current study had
adequate statistical power to evaluate individual and SNP
combination effects in relation to prostate cancer. In par-
ticular, MDR has 80% statistical power to evaluate all
possible two-, three-, and four-way gene-gene interac-
tions with as low as 200 cases and 200 controls [55].
MDR remains effective even in the presence of 5% geno-
typing errors and/or 5% missing data [55]. It is antici-
pated that 5% of the about 13,000 possible interactions
among 24 apoptosis-related SNPs will result in approxi-
mately 650 significant relationships due to chance alone.
However, MDR coupled with permutation testing adjust
for multiple comparison bias. Given the low prediction
accuracy affiliated with the interaction between AKT3
and PRKCQ, our study findings require replication
within independent study sets. However, recent simula-
tion studies demonstrate that even modest disparities in
genotype allele frequencies among study participants of
independent study sets may interfere with the capacity to
replicate complex interactions [56]. Thus, to ensure
reproducibility within future studies, we plan to select
study sets with similar genetic architecture (i.e., ancestry
identification markers and SNP genotypes) as CGEMS
PCA case-control subjects.
Conclusion
In summary, we have identified a marginal interaction
between two apoptosis-related SNPs linked to PCA dis-
ease aggressiveness using SEN-guided MDR. Future
molecular and pre-clinical studies may help to clarify
the functionality of these genetic variants and their role
in PCA disease progression. Our state-of-the art bioin-
formatics approach will enable researchers to pre-pro-
cess millions of SNP interactions using GWAS or
cancer consortia genotype data. In order to replicate
findings within independent study sets, researchers will
have to ensure that comparative sub-populations have
the same genetic architecture and ancestry backgrounds.
Therefore, the application of SEN-guided MDR may
ultimately help researchers identify and validate gene-
gene and/or gene-environment interactions to serve as
effective cancer prognostication tools.
Methods
Study population
The Prostate, Lung, Colon, and Ovarian (PLCO) Cancer
Screening Trial is a randomized, well-designed, and
multi-center investigation sponsored and coordinated by
the National Cancer Institute (NCI) [57,58]. Between
1993 and 2001, the PLCO Trial recruited study partici-
pants aged 55 to 81 years old to evaluate the effect of
screening on disease specific mortality, relative to stan-
dard care. Men randomized to the PCA arm of the trial,
received annual PSA and DRE exams. For the current
study, 2,286 European-American men were included in
our study if they had GWAS data available through the
Cancer Genetic Markers of Susceptibility (CGEMS) data
portal. (http://cgems.cancer.gov/) [38]. The CGEMS
study population consists of nationally available genetic
data for nearly 500,000 sequence variants. Incident PCA
cases (488 non-aggressive and 687 aggressive) were iden-
tified through various sources including: screening
exams; reports from patients, physicians, or relatives; or
linkage with the National Death Index or state cancer
registries. Incident PCA cases were pathologically con-
firmed with aggressive (Gleason score ≥ 7 and tumor
stage III/IV) or non-aggressive [Gleason score (< 7) and
tumor stage I/II] disease. Controls (n = 1,111) were
matched to cases identified based on age, time since
initial screening, and year of blood draw using incidence
density sampling. All participants signed informed con-
sent documents approved by both the NCI and local
institutional review boards. Access to clinical and back-
ground data collected through examinations and ques-
tionnaires was approved for use by the PLCO.
Gene selection
A panel of 73 apoptosis-associated genes was selected
from published cancer epidemiology or molecular biology
studies as well as pathway databases and tools, including
Kyoto Encyclopedia of Genes and Genomes (KEGG, http://
www.genome.jp/kegg), Gene Ontology (GO), BioCarta
(http://www.biocarta.com), ProteinLounge (http://www.
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com) [59-63]. We searched PubMed for articles using
the following keywords: [(prostate OR prostatic) AND
(cancer OR neoplasms) AND apoptosis (gene variants OR
single nucleotide polymorphisms OR targets) AND
epidemiology]. Pathway tools, such as KEGG, BioCarta,
ProteinLounge, and Ingenuity were used to visualize gene-
gene and protein-protein interactions essential to regulat-
ing apoptosis [59-61,63]. The Entrez Gene database of the
National Center for Biotechnology Information (NCBI,
Figure 1 Visualization of the interaction among apoptosis-related sequence variants using Statistical Epistasis Network Modeling
(SEN)-guided MDR. The Statistical Epistasis Network (SEN) was generated using a pairwise interaction strength cut-off or 1%. Overall, the model
has 91 vertices (single SNPs), 80 edges (pairwise SNPs), and 18 components ("sub-networks” of vertices and edges). The largest connected
component, shown in the center and spanning the entire length of this model, has 24 vertices and 34 edges. Each number in Figure 1
corresponds with a specific apoptosis-related SNP analyzed in the current study, as summarized in Additional file 2.
Table 4 Multi-dimensionality reduction models for apoptosis-related markers in relation to aggressive prostate cancer
(PCA)
Best Model Cross Validation
Consistency (CVC)*
Average Testing
Accuracy (ATA)*
Permutation Testing
p value*
One Factor
AKT3 rs2125230
9/10 0.512 0.282
Two Factor
AKT3 rs2125230
PRKCQ rs571715
9/10 0.563 0.011
Three Factor
AKT3 rs2125230
BID rs366542
PRKCQ rs571715
6/10 0.529 0.127
Four Factor
AKT3 rs2125230
BCL2L14 rs2448050
BID rs366542
TNFRSF1A rs4149576
2/10 0.517 0.321
*Adjusted for age and family history of prostate cancer (PCA)
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selected targets were involved in the apoptotic pathway
[64].
Criteria for SNP selection and data management
Prior to uploading our initial list (i.e., 73 apoptosis genes)
into the CGEMS data portal, we secured the HUGO gene
name equivalents for the targets of interest using NCBI
Entrez Gene. SNP profile data was available for more than
1197 SNPs [38]. However, upon further investigation,
many of these SNPs were eliminated if they were: not
located within 2.5 kb of the 5’ or 3’ end of the gene; or
detected within a gene that was not related to apoptosis.
Among SNPs that were associated with apoptosis, we
focused on gene regions located in coding, promoter, or
“near gene” regions. “Near gene” regions were defined as
2.5 kb up- and downstream of the 5’ or 3’ ends of the
selected genes, respectively.
We excluded any sequence variants that had a minor
allele frequency (MAF) < 5% as reported in the NCBI
Entrez SNP [64]. In addition, one SNP was removed since
its genotype frequency distribution among controls
deviated substantially from the Hardy-Weinberg Equili-
brium, p ≤ 0.005 (n = 1). Following data cleanup, 172
apoptotic SNPs were analyzed among 2,286 men of Eur-
opean descent (687 aggressive cases, 488 non-aggressive
cases, and 1,111 controls).
Predicted function of selected SNPs
The SNPinfo (http://snpinfo.niehs.nih.gov/) webserver
enabled us to annotate and/or predict the functional con-
sequence of selected apoptosis variants, as summarized in
Additional file 2 [65]. This server consists of several pipe-
lines to predict whether alternative alleles of a SNP may
alter one or more of the following: transcriptional regula-
tion via transcription factor binding site (TFBS) activity;
premature termination of amino-acid sequence (stop
codons); the splicing pattern or efficiency at mRNA splice
sites, exonic splicing enhancers (ESE) or silencers (ESS);
protein structures or properties by changing single amino
Figure 2 Interaction Entropy model. This graphical model, describes the percent entropy that is explained by each apoptosis-related SNP or
pairwise combination within our study population. Positive percent entropy indicates information gain (IG) or synergy; whereas, negative
percent indicates redundancy or lack of information gain (IG). Schematic coloration used in the visualization tools represents a continuum from
synergy (i.e. non-additive) to redundancy. The colors range from red representing a high degree of synergy (positive information gain (IG)),
orange a lesser degree, and gold representing independence and a midway point between synergy and redundancy. On the other hand, green
and blue represent redundancy, which is not apparent in the current analysis.
Lavender et al. BMC Medical Genomics 2012, 5:11
http://www.biomedcentral.com/1755-8794/5/11
Page 10 of 15acids (i.e., non-synonymous SNPs); or mRNA transcrip-
tion or protein translation by altering microRNA (miRNA)
binding sites.
Statistical analysis for single gene effects
Univariate and multivariate analyses were used to evalu-
ate apoptosis associated SNPs among men of European
descent in relation to PCA outcomes. To assess whether
possession of one or more apoptotic alleles influence the
risk of developing PCA, we tested for significant differ-
ences in the distribution of homozygous major, heterozy-
gous, or homozygous minor genotypes between cases
and controls using the chi-square test of heterogeneity.
A case-only analysis was used to examine the relationship
between apoptosis-related alleles and aggressive PCA.
We evaluated differences in the distribution and inheri-
tance of apoptosis-related genes comparing men with
aggressive disease (Gleason score ≥ 7 and tumor stage >
2) to those with non-aggressive disease (i.e., other PCA
cases that did not have both Gleason score ≥ 7a n d
tumor stage > 2). The associations between PCA out-
comes and selected polymorphic genes, expressed as
odds ratios (ORs) and corresponding 95% confidence
intervals (CIs), were estimated using unconditional multi-
variate logistic regression (LR) models adjusted for age
and family history of PCA. LR analyses for genetic var-
iants and PCA outcomes were conducted using the
major or common genotype as the referent category. All
chi-square test and LR analyses were conducted using
SAS 9.2 (SAS Institute Inc., Cary, NC) and SVS software
(Golden Helix, Inc., Bozeman, MT). Statistical signifi-
cance was assessed using a p-value < 0.05. Adjustments
for multiple comparisons were made using Bonferroni
correction and permutation testing.
Statistical power
We performed calculations to determine the statistical
power of our sample to detect significant relationships
between apoptosis-related polymorphisms and PCA devel-
opment. The expected risk estimates of our study were
determined by specifying values for a number of para-
meters, including: an average minor allele frequency of at
least 26.0%, NCI’s estimate of PCA disease prevalence
(19%); statistical power (80%); sample size (1,175 PCA
cases and 1,111 disease-free individuals or 687 aggressive
PCA cases and 488 non-aggressive cases). We assumed
the outcome was in complete linkage disequilibrium with
an apoptosis-predisposing variant (r
2 = 1.0). Based on the
aforementioned parameters, we have > 80% power to
detect genetic markers with odds ratios (ORs) of ≥ 1.4 (or
0.71 for protective effects) for PCA risk and ≥ 1.6 (or 0.62
for protective effects) for disease aggressiveness, assuming
a codominant model with 1 degree of freedom (df). Power
calculations were performed using Power for Genetic
Association Version 2 Software [66].
Analysis of gene interactions using multi-factor
dimensionality reduction (MDR)
To evaluate the single- and joint- modifying effects of 172
candidate apoptosis-related SNPs within a large dataset,
such as CGEMS, is computationally challenging [67,68]. In
order to overcome this problem, open-source and freely
available MDR 2.0 software (htpp://http://www.epistasis.
org) was used to analyze interactions among apoptotic
sequence variants in relation to PCA outcomes [69]. MDR
is a data reduction approach, designed to detect and char-
acterize high-order interactions in case-control studies.
With MDR, information from various genetic loci is cate-
gorized into high-risk or low-risk groups of disease. The
resulting one-dimensional multi-locus genotype variable is
then evaluated for its ability to classify and predict a dis-
ease outcome through cross-validation and permutation
testing. MDR uses a 10-fold cross validation to estimate
the testing accuracy of a model by leaving out 1/10
th of
the data as an independent test set. The model is devel-
oped on 9/10
th o ft h ed a t aa n dt h e ne v a l u a t e do nt h e
remaining test set. This process is repeated for each 1/10
th
of the data and the resulting prediction accuracies are
averaged.
In the current study, the model with the greatest cross
validation consistency (i.e., CVC ≥ 8/10) and highest pre-
diction accuracy [i.e., Average Testing Accuracy (ATA)]
w a ss e l e c t e da st h eb e s tp r e d i c t o ro fd i s e a s eo u t c o m e .
Accuracy is a function of the percentage of true positives
(TP), true negatives (TN), false positives (FP), and false
negatives (FN) as defined as (TP + TN)/(TP + TN + FP +
FN). ATAs are averaged across all 10 pieces of the data, in
order to provide an estimate of the predictive ability of the
loci in relation to the outcome of interest. We used cross-
validation consistency (CVC) to measure the degree to
which the same best MDR model was selected across the
10 divisions of the data. Models with a CVC of ≥ 8/10
using a 10-fold cross-validation were considered more
carefully. If the MDR model met the CVC criteria, we
selected models that had the highest ATAs. The combina-
tion of CVC and permutation testing were used to control
for multiple hypothesis testing. Permutation testing results
were statistically significant at the ≤ 0.05 level.
The current version of MDR used in this study enabled
the incorporation and adjustment of multiple covariates
[70]. To remove the covariate effects [i.e., age-group and
family history of PCA (yes or no)], we integrated two
sampling methods (i.e., over- and under-sampling). This
approach is computationally efficient, since it allows for
the adjustment of multiple covariates without signifi-
cantly increasing computational burden.
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entropy algorithms, hierarchical graphs and statistical
epistasis network (SEN)
The interaction entropy algorithm, based on information
theory, is a method to verify, visualize, and interpret com-
bination effects identified by parametric (e.g., LR) and
non-parametric (e.g., MDR) statistical test [43,71-74].
Jakulin and Brakto (2003) have developed a metric to
gauge whether the gain in information (i.e., information
gain) about a class variable (i.e., ability to predict disease
status) from a combination of two variables provides more
information than each variable considered independently
[72,73]. In the current study, measures of interaction were
used to build interaction entropy graphs to visualize and
interpret interactions among selected apoptosis-related
markers in relation to PCA risk and disease progression.
Individual and all possible pairwise loci were assigned a
mutual information (I) percentage score in relation to dis-
ease risk or aggressiveness; whereby typical scores for
genetic loci are < 5%. Pairwise SNP combinations were
deemed important if the joint mutual information [I =
(SNP1,S N P 2; disease status)] was greater than the total
mutual information of each individual locus considered
separately [I (SNP1; disease status) + I (SNP2; disease sta-
tus)]. Interactions were further visualized using an interac-
tion entropy graph, which uses a color-coding scheme to
interpret interactions. Strong interacting factors, coded
either red or orange, indicated high and medium levels of
synergistic effects on outcomes, respectively. Weak inter-
acting factors, coded either blue or green, denoted high or
modest levels of redundancy between markers, respec-
tively. Gold depicted indepe n d e n c ea n dam i d w a yp o i n t
between synergy and redundancy. Design of interaction
entropy graphs was accomplished using the Orange soft-
ware [75].
An important limitation of any gene-gene interaction
analysis method is the combinatorial nature of the pro-
blem. Exhaustive analysis of all possible two-, three-, four-
way combinations of SNPs creates a computational burden
and significant multiple testing problems. We addressed
this issue by pre-processing the data using statistical epista-
sis network (SEN) modeling, which has been described
elsewhere [39]. Briefly, this tool uses information theory, as
previously described, to develop a network based on the
amount of mutual information from SNP1,S N P 2,a n da
class variable (i.e., disease status). Thus, it describes the
pairwise interactive effect on a discrete outcome. An epis-
tasis network, or graph, consists of a set of vertices (indivi-
dual SNPs) and edges (pairwise interactions) that attach
the vertices. In the current study, the statistical epistasis
networks (SEN) were built by incrementally adding edges
if their strengths were greater than a given threshold.
Each vertex and each edge connecting two vertices were
assigned a weight commensurate with the strength of main
and interactive effects, respectively. The weight of a vertex
is depicted by its size; whereby, a larger size is indicative of
a higher main effect. Similarly, the thickness of the line
between SNP pairs is directly proportional to the strength
of their interaction.
We used SEN to visually summarize the strongest indi-
vidual SNP effects and SNP-pairwise interactions. The
topology of the graph, consisting of SNPs and their pair-
wise interactions, was used to guide MDR modeling. This
resulted in a reduction in the total number of SNP combi-
nations. For instance, we reduced the gene-gene interac-
tion analysis from 172 to 24 SNPs that resided within the
major connected component with the largest number of
vertices (i.e., main effects). The derived major component
plot was validated by comparing: (1) the number of ver-
tices and edges among the various connected “sub-net-
works”; and (2) the size of the major component plot of
real data versus randomized data that underwent 1000
permutations. The latter compared data using a pairwise
interaction strength cut-off of 1% and significance level of
0.05. To ensure that no significant interactions were iden-
tified, non-informative SNPs outside the major component
plot were also analyzed by MDR. In essence, SEN-guided
MDR facilitated logical prioritization of SNPs for gene-
gene interaction analysis in relation to PCA outcomes.
Additional material
Additional file 1: Table S1. Corresponding Gene and dbSNP IDs for
apoptosis-related sequence variants depicted in the Statistical Epistasis
Network Modeling Graph, presented in Figure 1.
Additional file 2: Table S2. Functional consequence of selected
apoptosis-related Polymorphisms.
Abbreviations
PCA: (PCA); SNP: (single nucleotide polymorphism); MDR: (multifactor
dimensionality reduction); SEN: (Statistical Epistasis Network).
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